This Week - Linksolution and GC Genome to List on KOSDAQ; Institutional Bookbuilding for GFC Life Science and Others
South Korea’s IPO market sees Linksolution and GC Genome debut on KOSDAQ this week, while GFC Life Science and others set IPO prices through institutional bookbuilding.
[GC Genome Listing②] Internal Transaction Committee Pledged, but 'Risks Remain'
GC Genome’s IPO faces ongoing regulatory risks over internal transactions, as South Korea’s antitrust watchdog intensifies scrutiny of the biotech sector.
[GC Genome Listing③] Overlapping Listings Among GC Group Affiliates Raise Concerns Over Shareholder Value
GC Genome’s IPO highlights concerns over overlapping listings within GC Group, raising fears of shareholder value dilution and renewed scrutiny of the “Korea Discount.”
GC Genome's planned dual listing has sparked concerns over conflicts of interest between parent and subsidiary shareholders due to high intra-group transactions, with experts warning of potential negative impacts on share price and the Korea Discount.
#YonhapInfomax #GCGenome #DualListing #InternalTransactions #KoreaDiscount #ShareholderConflict #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=65339
[GC Genome Listing④] Parent-Subsidiary Conflict of Interest Issues
GC Genome's planned dual listing has sparked concerns over conflicts of interest between parent and subsidiary shareholders due to high intra-group transactions, with experts warning of potential negative impacts on share price and the Korea Discount.
GC Genome Sets IPO Price at Top End Following Strong Institutional Demand—547 to 1 Bid Ratio
GC Genome set its IPO price at the top of its range after institutional demand reached a 547-to-1 bid ratio, raising 42 billion won and targeting KOSDAQ listing in June.
South Korea’s IPO market sees Linksolution and GC Genome launch retail subscriptions this week, while Dow InSys and others begin institutional demand forecasting, with total offerings exceeding $70 million.
#YonhapInfomax #IPO #Linksolution #GCGenome #DowInSys #DemandForecasting #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=64670
This Week - Linksolution, GC Genome Open IPO Subscriptions—Demand Forecasting for Dow InSys and Others Underway
South Korea’s IPO market sees Linksolution and GC Genome launch retail subscriptions this week, while Dow InSys and others begin institutional demand forecasting, with total offerings exceeding $70 million.
GC Genome - 'Changing Cancer Early Detection Paradigm... Aiming for Top-Tier Status'
GC Genome aims to revolutionize early cancer detection with innovative liquid biopsy technology, targeting global leadership in clinical genomics analysis through upcoming IPO.
Yonhap Infomax News